Arthur M. Cohen & Associates LLC Has $3.02 Million Position in Johnson & Johnson (NYSE:JNJ)

Arthur M. Cohen & Associates LLC reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 24.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,035 shares of the company’s stock after selling 5,554 shares during the period. Arthur M. Cohen & Associates LLC’s holdings in Johnson & Johnson were worth $3,019,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Magnolia Capital Management Ltd. increased its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after buying an additional 55 shares during the period. Howard Financial Services LTD. increased its stake in shares of Johnson & Johnson by 2.1% in the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares during the period. American Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 2.1% in the first quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after buying an additional 57 shares during the period. Capital Investment Counsel Inc increased its stake in shares of Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after buying an additional 59 shares during the period. Finally, Kwmg LLC increased its stake in shares of Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares during the period. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $173.91 on Tuesday. The firm’s 50-day moving average price is $175.84 and its 200-day moving average price is $174.50. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The firm has a market capitalization of $457.63 billion, a P/E ratio of 25.31, a P/E/G ratio of 3.32 and a beta of 0.59. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter in the prior year, the business earned $2.48 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.60%. Johnson & Johnson’s dividend payout ratio is presently 65.79%.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. SVB Leerink decreased their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Citigroup decreased their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. UBS Group decreased their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.